Program
Anti-TMPRSS6 Monoclonal Antibody DISC-3405
Also written as “DISC-3405” and “9MW3011”.
Its studies are mostly in Polycythemia Vera · Anemia, Sickle Cell · beta-Thalassemia, led by 2 companies.
Drug pageAnti-TMPRSS6 Monoclonal Antibody DISC-3405: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Disc Medicineits history only | 32 open or running | phase 2since May 7, 2025 | Sep 7, 2023 | Jun 2027phase 1 · NCT07187973 |
| Mabwell (Shanghai) Bioscience | 32 open or running | phase 1since Feb 25, 2024 | Feb 25, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Mabwell (Shanghai) Bioscience only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 25, 2024First study: phase 1 study in HealthyFirst studyNCT06389942 · 48 enrolled · China
- Dec 23, 2024Phase 1 study in Polycythemia VeraNCT06752746 · 108 planned · China
- Jan 9, 2025Phase 1 study in beta-ThalassemiaNCT06772766 · 40 planned · China
TargetBeta
“A humanized monoclonal antibody directed against transmembrane serine protease 6 (TMPRSS6; matriptase-2), that can potentially be used to regulate TMPRSS6, hepcidin and iron levels and treat iron overload and anemia associated with certain disorders such as polycythemia vera (PV), beta thalassemia, ”NCIt, by rule
Other programs on TMPRSS6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sapablursenrule | Ionis Pharmaceuticals | phase 3 | 4 |
| AG-236rule | Agios Pharmaceuticals | phase 3 | 2 |
Studies
All 3 Mabwell (Shanghai) Bioscience leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06772766beta-Thalassemia · China | 1 | Recruiting | Oct 2026 | 40 |
| NCT06752746Polycythemia Vera · China | 1 | Recruiting | Aug 31, 2025 | 108 |
| NCT06389942Healthy · China | 1 | Completed | May 31, 2024 | 48 |
How it is read
Names in the registry
- “DISC-3405”, 4 entries
- “9MW3011”, 3 entries
Conditions, from the studies’ own filings
- Polycythemia Vera, 2 studies
- Anemia, Sickle Cell, 1 study
- beta-Thalassemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.